Bottom line
Is PJP a good fund? The bottom line
PJP is an actively managed health care sector ETF from Invesco.
Its expense ratio is 0.58% — about $58 a year on every $10,000 invested, cheaper than 79% of health care sector funds we track.
It returned +27.9% over one year, +9.0% a year over five years, +5.1% a year over ten (as of Dec 31, 2025, per its prospectus).
With $472 million in net assets and 33 holdings, its largest position is Invesco Private Prime Fund (7.9%) and the top 10 make up 53.7% of the portfolio.
What stands out
- Low cost: cheaper than 79% of health care sector peers
- 5-year return beat 96% of category peers
What to watch
- Concentrated: top 10 holdings are 53.7% of assets
Updated Nov 19, 2026
What PJP invests in
The Invesco Pharmaceuticals ETF (the Fund) seeks to track the investment results (before fees and expenses) of the Dynamic Pharmaceutical Intellidex Index (the Underlying Index).
The Fund is an index fund that seeks to track the investment results of the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC (ICE Data or the Index Provider) compiles and maintains the Underlying Index, which is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. In accordance with the Underlying Index methodology, the various types of companies may include companies from the following segments of the pharmaceutical industry: ? Big Pharmaceutical: Large, vertically integrated drug companies that actively participate in all major phases of the drug development process, including research and development, animal and human testing, manufacturing and sales and marketing. ?…
From the fund's prospectus (filed Aug 27, 2026).
PJP performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PJP | +27.9% | +9.0% | +5.1% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What PJP costs
On a $10,000 investment, PJP's 0.58% expense ratio costs about $58 a year. The prospectus estimates $726 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
PJP top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Invesco Private Prime Fund | 7.93% |
| 2 | Abbott Laboratories | 5.67% |
| 3 | AbbVie Inc. | 5.48% |
| 4 | Amgen Inc. | 5.33% |
| 5 | Johnson & Johnson | 5.18% |
| 6 | Merck & Co., Inc. | 5.06% |
| 7 | Eli Lilly and Co. | 5.02% |
| 8 | Corcept Therapeutics Inc. | 4.96% |
| 9 | Gilead Sciences, Inc. | 4.53% |
| 10 | Pfizer Inc. | 4.50% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 53.7% of the fund. See all top 25 holdings and asset mix →